# Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

DOI: 10.1111/jth.13912
Journal of Thrombosis and Haemostasis, 2018, 16, 209-219.

| # | Paper | IF | Citations |
|---|---|---|---|
| 220 | Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. **2018**, 2, 251-265 | | 23 |
| 219 | Venous thromboembolism controversies. **2018**, 64, 408-444 | | 2 |
| 218 | The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs. **2018**, 168, 63-66 | | 10 |
| 217 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. **2018**, 20, 1231-1242 | | 148 |
| 216 | The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. **2018**, 39, 1330-1393 | | 1094 |
| 215 | Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. **2018**, 16, 28 | | 25 |
| 214 | Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 2462-2470 | 15.4 | 10 |
| 213 | Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban. **2018**, 24, 188S-193S | | 0 |
| 212 | The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation. **2018**, 171, 160-166 | | 14 |
| 211 | Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. **2018**, 73, 1557-1563 | | 9 |
| 210 | Testing and monitoring direct oral anticoagulants. **2018**, 132, 2009-2015 | | 39 |
| 209 | The use of direct oral anticoagulants in chronic kidney disease. **2018**, 183, 170-184 | | 24 |
| 208 | FXa Direct Synthetic Inhibitors. **2018**, | | 2 |
| 207 | Evaluation of a rapid centrifugation step (4500 g for 2 min) in coagulation assays to monitor direct oral anticoagulants. **2018**, 57, e37-e40 | | 0 |
| 206 | Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?. **2018**, 23, 388-399 | | 14 |
| 205 | Direct oral anticoagulants: When to consider laboratory testing?. **2018**, 40 Suppl 1, 30-33 | | 8 |
| 204 | Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. **2018**, 36, 801-803 | | 3 |

| | | | |
|---|---|---|---|
| 203 | Evaluation of the DOAC-Stop Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. **2018**, 2, e202-e209 | | 45 |
| 202 | Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: Assessment of the performance of a rapid centrifugation method. **2018**, 40, e105-e108 | | 7 |
| 201 | Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers. **2019**, 3, 391-396 | | 20 |
| 200 | A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove. **2019**, 187, 377-385 | | 22 |
| 199 | Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. **2019**, 3, e210-e215 | | 1 |
| 198 | Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation. **2019**, 184, 8-15 | | 2 |
| 197 | DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119). **2019**, 182, 101-109 | | 2 |
| 196 | Reversion algorithm for patients anticoagulated with dabigatran in urgent surgery. **2019**, 66, 149-156 | | |
| 195 | Perioperative management of anticoagulant therapy. **2019**, 4, 144-151 | | 1 |
| 194 | Edoxaban plasma levels in patients with non-valvular atrial fibrillation: Inter and intra-individual variability, correlation with coagulation screening test and renal function. **2019**, 175, 61-67 | | 6 |
| 193 | Clinical impact of direct oral anticoagulant measuring in a real-life setting. **2019**, 175, 40-45 | | 6 |
| 192 | Progress in the monitoring of direct oral anticoagulant therapy. **2019**, 184, 912-924 | | 21 |
| 191 | Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. **2019**, 8, 19 | | 15 |
| 190 | Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. **2019**, 266, 2263-2272 | | 13 |
| 189 | Recommendations for clinical laboratory testing of activated protein´C resistance; communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1555-1561 | 15.4 | 12 |
| 188 | Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. **2019**, 75, 1069-1075 | | 14 |
| 187 | Oral anticoagulant monitoring: Are we on the right track?. **2019**, 41 Suppl 1, 40-48 | | 4 |
| 186 | Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1354-1362 | 15.4 | 17 |

| | | | |
|---|---|---|---|
| 185 | An update on laboratory assessment for direct oral anticoagulants (DOACs). **2019**, 41 Suppl 1, 33-39 | | 35 |
| 184 | What have we learned from coagulation laboratory participation in external quality programs?. **2019**, 41 Suppl 1, 49-55 | | 2 |
| 183 | Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1064-1072 | 15.4 | 43 |
| 182 | The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. **2019**, 23, 98 | | 467 |
| 181 | Andexanet alfa for the reversal of factor Xa inhibitors. **2019**, 19, 387-397 | | 5 |
| 180 | In vitro assessment of edoxaban anticoagulant effect in pediatric plasma. **2019**, 178, 112-118 | | 2 |
| 179 | Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. **2019**, 19, 525-539 | | 5 |
| 178 | Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. **2019**, 15, 381-398 | | 21 |
| 177 | Reversion algorithm for patients anticoagulated with dabigatran in urgent surgery. **2019**, 66, 149-156 | | |
| 176 | Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. **2019**, 30, 2823-2833 | | 8 |
| 175 | A New Test for the Detection of Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in the Emergency Room Setting. **2019**, 1, e0024 | | 3 |
| 174 | Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018. **2019**, 18, 143-166 | | 16 |
| 173 | Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. **2019**, 41, 250-261 | | 7 |
| 172 | A level-headed approach to measuring direct oral anticoagulants: A 2-year retrospective analysis of DOAC levels from a tertiary UK centre. **2019**, 41, 200-207 | | 5 |
| 171 | Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. **2019**, 47, 590-595 | | 9 |
| 170 | Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator. **2019**, 53, 341-347 | | 19 |
| 169 | Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants. **2019**, 30, 322-333 | | 8 |
| 168 | Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. **2019**, 184, 808-816 | | 25 |

| | | | |
|---|---|---|---|
| 167 | International external quality assessment for measurements of direct oral anticoagulants: results and recommendations. **2020**, 188, 460-464 | | 4 |
| 166 | Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. **2020**, 21, e7 | | 1 |
| 165 | Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants. **2020**, 185, 72-77 | | 1 |
| 164 | Routine Therapeutic Drug Monitoring of Dabigatran: Experience at a Tertiary Center. **2020**, 42, 468-472 | | 2 |
| 163 | Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests. **2020**, 15, e0240483 | | 1 |
| 162 | The relationship between DOAC levels and clinical outcomes: The measures tell the tale. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 3163-3168 | 15.4 | 6 |
| 161 | [The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. **2020**, 107, 574-585 | | 0 |
| 160 | Perioperative management of anticoagulation. **2020**, 48, 231-240 | | 0 |
| 159 | Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants. **2020**, 10, 12221 | | 2 |
| 158 | Impact of specific preclinical variables on coagulation biomarkers in cancer-associated thrombosis. **2020**, 191 Suppl 1, S26-S30 | | |
| 157 | Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists. **2020**, 29, 104691 | | 6 |
| 156 | Outcomes and anticoagulation use for elderly patients that present with an Acute Hip Fracture: multi-centre, retrospective analysis. **2020**, | | 3 |
| 155 | Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia. **2020**, 196, 539-540 | | 1 |
| 154 | Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism. **2020**, 195, 231-232 | | |
| 153 | Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs). **2020**, 6, 241-259 | | 4 |
| 152 | Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. **2020**, 18, 733-741 | | 3 |
| 151 | Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. **2020**, 40, 1001-1008 | | 3 |
| 150 | Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study. **2020**, 26, 1076029620972473 | | 2 |

| | | | |
|---|---|---|---|
| 149 | Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a´multidisciplinary expert advisory board. **2020**, 28, 504-513 | | 0 |
| 148 | Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). **2020**, 60, 29 | | 3 |
| 147 | Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. **2020**, 191, 347-362 | | 5 |
| 146 | Evaluation of the analytical performances of FibWave, a new sensitive tool assessing the fibrin clot formation, to measure the effects of anticoagulants. **2020**, 191, 78-81 | | 3 |
| 145 | Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. **2020**, 42, 636-642 | | 12 |
| 144 | What gastroenterologists should know about direct oral anticoagulants. **2020**, 52, 1115-1125 | | 6 |
| 143 | Pharmacological Review of Anticoagulants. **2020**, | | 1 |
| 142 | MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. **2020**, 20, 86 | | 1 |
| 141 | Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?. **2020**, 8, 741-747 | | |
| 140 | Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1653-1660 | 15.4 | 1 |
| 139 | Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age-related macular degeneration. **2020**, 12, 2515841420903929 | | 2 |
| 138 | Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. **2020**, 50, 371-379 | | 0 |
| 137 | Quelle place pour la biologie chez les patients traités par anticoagulants oraux directs ?. **2020**, 2020, 42-47 | | 2 |
| 136 | Endovascular Stroke Treatment and Risk of Intracranial Hemorrhage in Anticoagulated Patients. **2020**, 51, 892-898 | | 18 |
| 135 | Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. **2020**, 49, 395-403 | | 4 |
| 134 | Ecarin based coagulation testing. **2020**, 95, 863-869 | | 8 |
| 133 | Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. **2020**, 13, 777-784 | | 6 |
| 132 | Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents. **2020**, 190, 103-111 | | 6 |

| | | | |
|---|---|---|---|
| 131 | Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1866-1873 | 15.4 | 9 |
| 130 | The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients. **2021**, 145, 99-104 | | 3 |
| 129 | The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. **2021**, 87, 2247-2255 | | 6 |
| 128 | Limitations of a calibrated, quantitative APC-R assay under routine conditions. **2021**, 43, 318-323 | | 3 |
| 127 | Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. **2021**, 43, 7-20 | | 8 |
| 126 | DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples. **2021**, 5, 314-325 | | 5 |
| 125 | Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors. **2021**, | | 1 |
| 124 | Advances in the Management of Cancer-Associated Thrombosis. **2021**, 47, 139-149 | | 5 |
| 123 | Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. **2021**, 47, 150-160 | | 3 |
| 122 | 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. **2021**, 121, 1008-1020 | | 21 |
| 121 | The relationship between DOAC levels and clinical outcomes: The measures tell the tale-Response from original authors Lijfering et al. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 1136-1138 | 15.4 | 0 |
| 120 | Updates in Anticoagulation Therapy Monitoring. **2021**, 9, | | 7 |
| 119 | Coagulopatí inducida por trauma. Revisió basada en la evidencia y propuesta de manejo. **2021**, | | |
| 118 | Direct oral anticoagulant plasma level measurement in clinical practice: A French single-institution retrospective study. **2021**, 200, 83-86 | | 0 |
| 117 | 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. **2021**, 23, 1612-1676 | | 99 |
| 116 | Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon. **2021**, 37, 273-279 | | |
| 115 | Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: An observational study. **2021**, 5, e12528 | | 0 |
| 114 | Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses. **2021**, 44, 724-732 | | 1 |

| | | |
|---|---|---|
| 113 | Direct oral anticoagulant blood level monitoring in daily practice. **2021**, 3, 100049 | 1 |
| 112 | Venous Thromboembolism While on Anticoagulation With Apixaban. **2021**, 13, e15189 | |
| 111 | Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection. **2021**, 12, 679431 | |
| 110 | Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study. **2021**, 21, 669-679 | 4 |
| 109 | Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa. **2021**, 43, 795-801 | 2 |
| 108 | Measuring apixaban levels in the elderly patient with non-valvular atrial fibrillation. **2021**, 335, 57-58 | |
| 107 | Antithrombotic and Antiplatelet Drug Toxicity. **2021**, 37, 591-604 | 3 |
| 106 | Review of coagulation preanalytical variables with update on the effect of direct oral anticoagulants. **2021**, 43 Suppl 1, 109-116 | 2 |
| 105 | New Trends and Advances in Non-Variceal Gastrointestinal Bleeding-Series II. **2021**, 10, | 1 |
| 104 | Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs - A Systematic Review and Meta-analysis. **2021**, 5, e438-e448 | 2 |
| 103 | [Management of bleeding in patients on antithrombotic therapy]. **2021**, 116, 491-498 | |
| 102 | Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran. **2021**, 53, 623-627 | |
| 101 | Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients. **2021**, 10, | 1 |
| 100 | Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements. **2021**, 8, 717939 | 0 |
| 99 | Can direct oral anticoagulants be used in kidney transplant recipients?. **2021**, e14474 | 0 |
| 98 | STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. **2021**, 35, 2569-2591 | 8 |
| 97 | A validated UPLC-MS/MS method for the determination of CX3002 in human plasma and its application to a pharmacokinetic study. **2021**, 1183, 122954 | 0 |
| 96 | Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery. **2021**, 78, 867-874 | |

| | | | |
|---|---|---|---|
| 95 | STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. **2021**, 112, 981-1004 | | 5 |
| 94 | Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury. **2021**, 10600280211046087 | | 1 |
| 93 | Apixaban Level and Its Influence on Immunosuppression and Graft Outcome in Kidney Transplant Recipients With Atrial Fibrillation. **2021**, 43, 637-644 | | 0 |
| 92 | Development and validation of an ultra-high performance liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of direct oral anticoagulants in human plasma. **2021**, 1182, 122952 | | 0 |
| 91 | A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study. **2021**, 206, 76-83 | | 1 |
| 90 | The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. **2021**, 27, 10760296211044722 | | |
| 89 | Gestion pEiopEatoire des anticoagulants oraux directs. **2019**, 2019, 2-6 | | 1 |
| 88 | Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. **2021**, 28, 611-621 | | 7 |
| 87 | A Novel Laboratory Assay to Monitor Unfractionated Heparin Dosing in Patients Taking Apixaban Prior to Hospital Admission. **2021**, 6, 378-386 | | 2 |
| 86 | Evaluation of a new thromboplastin reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, international normalized ratio and extrinsic factor levels. **2020**, 42, 650-660 | | 3 |
| 85 | Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2003-2017 | 15.4 | 16 |
| 84 | Periendoscopic management of direct oral anticoagulants: a prospective cohort study. **2019**, 68, 969-976 | | 15 |
| 83 | Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. **2020**, 30, 010702 | | 6 |
| 82 | Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels. **2021**, 132, 707-716 | | 3 |
| 81 | [Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake]. **2019**, 59, 28-35 | | 3 |
| 80 | Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. **2020**, 18, 486-495 | | 5 |
| 79 | The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management. **2019**, 94, 40-56 | | 4 |
| 78 | "Accessory After the Factors": A Rare Case of an Acquired Factor VIII Inhibitor in a 75-Year-Old Man on Rivaroxaban. **2021**, 13, e18597 | | |

| | | | |
|---|---|---|---|
| 77 | Impact of centrifugation time and pneumatic tube transport on plasma concentrations of direct oral anticoagulants. **2021**, | | |
| 76 | Update on laboratory testing and hemostasis assessment in patients receiving direct oral anticoagulants (DOACs). **2021**, 5, 100084 | | 0 |
| 75 | The effects of direct oral anticoagulants on congenital thrombophilia. **2018**, 29, 20-27 | | |
| 74 | Epidural hematoma after total knee arthroplasty in a patient receiving rivaroxaban - A case report -. **2019**, 14, 102-105 | | 1 |
| 73 | Prise en charge h□mostatique des h□morragies c□□brales sous anticoagulants oraux. **2019**, 28, 363-370 | | |
| 72 | Anticoagulation Using Rivaroxaban for VTE Treatment: Dose Adjustment According to Thrombus Volume. **2020**, 31, 89-93 | | |
| 71 | Periprocedural Management of Oral Anticoagulation. **2020**, 104, 709-726 | | 8 |
| 70 | Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban. **2020**, 96-104 | | |
| 69 | Laboratory Testing for the Antiphospholipid Syndrome. **2020**, 57-66 | | |
| 68 | Coagulation test and anti-factor Xa activity in patients treated with edoxaban. **2020**, 42, 80-83 | | |
| 67 | Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines. **2020**, 12, 327-334 | | 0 |
| 66 | Rivaroxaban induced spontaneous hemoperitoneum around terminal ileum and cecum clinically mimicking acute appendicitis in a young patient: First case report. **2020**, 2, 50-52 | | |
| 65 | Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. *Journal of Thrombosis and Haemostasis*, **2021**, 20, 92 | 15.4 | 3 |
| 64 | Early anticoagulant reversal after trauma: A Western Trauma Association critical decisions algorithm. **2021**, 90, 331-336 | | 3 |
| 63 | STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. **2021**, 53, 97-124 | | 1 |
| 62 | Pharmacologic Treatment of Pulmonary Embolism. **2022**, 143-170 | | |
| 61 | Ginkgo, Ginseng und Gerinnung. **2021**, 42, 301-311 | | 1 |
| 60 | Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography.. **2021**, 5, e570-e576 | | 0 |

| | | |
|---|---|---|
| 59 | Prothrombin complex concentrates for the urgent reversal of apixaban and rivaroxaban - an Australian retrospective cohort study. **2021**, | |
| 58 | A seesaw-type device to measure the coagulation time of blood: application to assessment of anticoagulant effect of direct oral anticoagulants (DOACs) in patients. **2021**, 35, 43-48 | |
| 57 | Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines.. **2022**, 39, 100-132 | 5 |
| 56 | Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors.. **2022**, 6, e12648 | 0 |
| 55 | Evaluation of DOAC Dipstick Test for Detecting Direct Oral Anticoagulants in Urine Compared with a Clinically Relevant Plasma Threshold Concentration.. **2022**, 28, 10760296221084307 | 1 |
| 54 | Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing - Evaluation on spiked and patient samples.. **2022**, 6, e12633 | 0 |
| 53 | Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy.. **2022**, 14, | 1 |
| 52 | Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.. **2022**, | 2 |
| 51 | Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex´vivo patient samples.. **2022**, | 0 |
| 50 | Direct oral anticoagulant (DOAC) interference in hemostasis assays. **2021**, 2021, 129-133 | 1 |
| 49 | The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.. **2022**, 6, e12680 | 1 |
| 48 | The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.. **2022**, 106994 | |
| 47 | Point of care coagulation management in anesthesiology and critical care.. **2022**, | 0 |
| 46 | Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.. **2022**, 9, 817826 | 0 |
| 45 | Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?. **2022**, 28, 10760296221096422 | 1 |
| 44 | Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney DiseaseRelationships With Renal Function and Clinical Events. **2022**, 13, | 0 |
| 43 | Rapid Assessment of Clinically Levels of Direct Acting Oral Anticoagulants ( DOAC ) in emergency room. | |
| 42 | Testing for Lupus Anticoagulants. | 0 |

| | | |
|---|---|---|
| 41 | Monitoring Anticoagulation. **2022**, 417-429 | |
| 40 | Are outpatient anticoagulation management services the wave of the future (again)?. **2022**, 6, | |
| 39 | Point of Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study. | 1 |
| 38 | Grundlagen des perioperativen Umgangs mit direkten oralen Antikoagulanzien. | |
| 37 | Gerinnungsdiagnostik im klinischen Alltag Teil 2. **2022**, 63, 736-750 | |
| 36 | A System-Wide Investigation and Stratification of the Hemostatic Proteome in Premature Myocardial Infarction. 9, | |
| 35 | Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study. | 1 |
| 34 | Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study. **2022**, 12, 1027 | |
| 33 | Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence. **2022**, | |
| 32 | Which Are the Best Techniques for Reducing the Incidence of Postoperative Deep Vein Thrombosis?. **2023**, 407-416 | |
| 31 | Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. **2022**, 06, e238-e247 | 0 |
| 30 | The Myths Behind DOAC Measurement: Analyses of Prescribing Information from Different Regulatory Bodies and a Call for Harmonization. | 0 |
| 29 | Evaluation of newly-developed modified diluted prothrombin time reagent in non-valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents. | 1 |
| 28 | Implementation of the new EUR IVD regulation and relation with ISO15189 accreditation: Guidance is urgently required for haemostasis testing. **2022**, 44, 71-78 | 1 |
| 27 | Thrombolysis in an Acute Ischemic Stroke Patient on Direct Anticoagulant Therapy Outside of the Traditional Time Window: A Case Report. **2022**, | 0 |
| 26 | Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti- X a concentrations. | 0 |
| 25 | A review of laboratory considerations in thrombophilia testing. **2022**, | 0 |
| 24 | Coagulation Assays and Direct Oral Anticoagulant Levels Among Patients Having an Elective Surgery or Procedure. | 0 |

| | | |
|---|---|---|
| 23 | The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function □A systematic review. **2022**, 107123 | 0 |
| 22 | Bilans d□□hostase sous anticoagulants oraux directs. **2022**, 32, 15-22 | 0 |
| 21 | Direct oral anticoagulants (DOACs): From the laboratory point of view. **2022**, 72, 459-482 | 0 |
| 20 | Impact of off-label under-dose direct oral anticoagulant on coagulation and fibrinolytic markers in patients with atrial fibrillation. | 0 |
| 19 | Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls. **2022**, 6, | 0 |
| 18 | The impact of direct oral anticoagulants on viscoelastic testing □A systematic review. 9, | 0 |
| 17 | Comparison of bleeding following gastrointestinal endoscopic biopsy in patients treated with and without direct oral anticoagulants. | 0 |
| 16 | Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon. **2022**, | 0 |
| 15 | Evaluation of Coaguchek□ Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study. **2022**, 1, | 0 |
| 14 | How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?. | 0 |
| 13 | Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study. **2022**, 12, | 0 |
| 12 | Clinically relevant increases in the INR and MELD score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis. **2023**, 100052 | 0 |
| 11 | Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness. **2023**, 12, 860 | 0 |
| 10 | Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing. **2023**, 5, 80-89 | 0 |
| 9 | DOACs plasma levels in relation to clinical outcome. How far have we come?. **2023**, 225, 16-21 | 0 |
| 8 | DOAC□ssociated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. **2023**, 21, 433-452 | 0 |
| 7 | Direct Oral Anticoagulants: Laboratory Challenges and Antidotes. **2023**, 43, 037-043 | 0 |
| 6 | To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. **2023**, 2023, 1-7 | 0 |

| | | |
|---|---|---|
| 5 | Above the Threshold Time of Coagulation: Delayed Diagnosis of Acquired Hemophilia A. **2023**, | 0 |
| 4 | Direct Oral Anticoagulants: How Do These Drugs Work, How to Monitor, and What Is Their Role in Orthopaedic Surgery. **2023**, 31, e347-e355 | 0 |
| 3 | Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters. **2023**, 12, 2236 | 0 |
| 2 | Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study. **2023**, 100139 | 0 |
| 1 | Volumetric Absorptive Microsampling Technique in the LC-MS Determination of Direct Oral Anticoagulants. **2023**, 23, 23-31 | 0 |